Case Overview

Introduction

In a strategically significant development for biopharmaceutical patent litigation, Regeneron Pharmaceuticals, Inc. voluntarily dismissed its appeal against Mylan NV, Celltrion, Inc., and Samsung Bioepis Co., Ltd. before the United States Court of Appeals for the Federal Circuit — just 160 days after filing. The case, docketed as Case No. 24-1567, centered on U.S. Patent No. US10888601B2, covering the use of a VEGF antagonist to treat angiogenic eye disorders — a high-value therapeutic category encompassing conditions such as wet age-related macular degeneration (AMD) and diabetic macular edema.

The voluntary dismissal, entered August 20, 2024, raises immediate questions about Regeneron’s patent enforcement posture in the rapidly evolving VEGF antagonist biosimilar landscape. For patent attorneys, IP professionals, and R&D leaders monitoring ophthalmic biologics patent litigation, this case offers critical insights into appellate strategy, biosimilar competition dynamics, and the litigation calculus that governs high-stakes pharmaceutical patent disputes.

The Parties

The Patent at Issue

This case involved a critical patent covering the use of VEGF antagonists, a high-value therapeutic category. The patent is registered with the U.S. Patent and Trademark Office (USPTO) and is key to the biopharmaceutical space.

• • US10888601B2 (Application No. US16/397267) — Use of a VEGF (Vascular Endothelial Growth Factor) antagonist to treat angiogenic eye disorders

Litigation Timeline & Procedural History

Filed: March 13, 2024, in the District of Columbia circuit before the Court of Appeals for the Federal Circuit — the exclusive appellate forum for U.S. patent matters.

The appeal’s 160-day lifespan is notably brief for Federal Circuit patent litigation, which typically spans 18–36 months through full briefing, oral argument, and decision. The case never progressed to substantive merits briefing; the dismissal was unopposed, indicating no contested procedural dispute at the appellate stage.

The Federal Circuit filing suggests this appeal arose from a prior district court or PTAB proceeding, though specific lower-court case data was not disclosed in the available record. The involvement of Celltrion and Samsung Bioepis as co-defendants alongside Mylan suggests coordinated biosimilar challenger litigation — a common pattern in BPCIA disputes where multiple biosimilar applicants file contemporaneously.

The Verdict & Legal Analysis

Outcome

On August 20, 2024, the Federal Circuit granted Regeneron’s unopposed motion to voluntarily dismiss the appeals pursuant to Federal Rule of Appellate Procedure 42. The court’s order specified that each party shall bear its own costs, a standard provision in voluntary dismissals that avoids fee-shifting and preserves commercial relationships — a detail worth noting in the context of ongoing biosimilar negotiations.

No damages were awarded. No injunctive relief was granted or denied. The dismissal was procedural rather than substantive — the Federal Circuit issued no ruling on patent validity, infringement findings, or claim construction.

Verdict Cause Analysis

The basis of termination is recorded as voluntary dismissal under an infringement action. Regeneron’s decision to file an unopposed motion — rather than a contested withdrawal — indicates the defendants raised no procedural objection, suggesting possible mutual agreement or a negotiated resolution outside the court record.

Several strategic interpretations merit consideration:

• Settlement or Licensing Agreement: Voluntary dismissals with each party bearing its own costs frequently signal confidential settlement negotiations, including licensing arrangements or agreed market-entry timelines for biosimilars.
• Mooting Event: Changes in patent status, product approval timelines, or concurrent PTAB proceedings can render an appeal moot, prompting voluntary withdrawal.
• Strategic Reassessment: Regeneron may have concluded that the appellate record was unfavorable or that alternative IP enforcement pathways — including additional patent families — offered stronger protection for its VEGF franchise.

Because specific lower-court findings were not included in the available case data, the precise triggering event for dismissal cannot be confirmed. The absence of a substantive Federal Circuit ruling means no binding precedent was established in this appeal.

Legal Significance

The lack of a merits ruling limits direct precedential impact. However, the case underscores a broader litigation trend: branded pharmaceutical companies increasingly deploy appeal proceedings as negotiation leverage rather than as vehicles for definitive judicial resolution. In the BPCIA (Biologics Price Competition and Innovation Act) biosimilar litigation framework, the 12-year exclusivity window and patent dance procedures create complex multi-party dynamics where appellate filings may serve strategic commercial functions independent of their ultimate judicial outcome.

Strategic Takeaways

For Patent Holders:

VEGF antagonist patent portfolios require layered protection across composition, method-of-use, and dosing claims to sustain enforcement against multiple biosimilar challengers simultaneously.

Voluntary dismissal preserves flexibility — patent holders retain the right to assert the same patent in future infringement actions absent a final judgment on the merits.

For Accused Infringers:

An unopposed voluntary dismissal without prejudice may leave litigation exposure unresolved; biosimilar applicants should assess whether res judicata or collateral estoppel bars future re-assertion.

Cost-bearing provisions (each party bears own costs) confirm this was a negotiated exit, not a concession of merit.

For R&D Teams:

Freedom-to-operate (FTO) analyses for VEGF antagonist products must account for remaining Regeneron patent family members beyond US10888601B2, as dismissal of one appeal does not eliminate the broader patent estate.